Strategic Distribution Diasorin has recently signed a strategic distribution agreement with McKesson for Liaison Nes point-of-care molecular diagnostic system, indicating strong channel expansion opportunities to scale sales through large US-based distribution networks.

Ce Marked Growth The launch of CE-marked LIAISON QuantiFERON-TB Gold Plus II signals a focus on expanding ASIA/EMEA pipeline with higher throughput assays, suggesting upsell potential for existing LIAISON users and cross-sell of advanced TB testing solutions.

Lifecycle Expansion Diasorin’s broadened Life Science capabilities since 2021 create cross-sell opportunities to academic and clinical labs seeking end-to-end reagent kits and workflow integration across diagnostic and research use cases.

Acquisition & Synergy Strategic assets from Luminex and related FCI units position Diasorin to upsell comprehensive multiplex and flow cytometry offerings, enabling cross-category bundles with existing IVD and life science portfolios.

Global Footprint With 35 subsidiaries, 10 manufacturing sites, and 9 R&D centers across five continents, there are scalable growth opportunities to tailor regional deployments, regulatory support, and service contracts for multinational healthcare customers.